# Is Retatrutide Legal? FDA, DEA and WADA Status | PepVault

Source: https://pepvault.app/peptides/retatrutide/legal-status

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Peptides](https://pepvault.app/peptides) [Retatrutide](https://pepvault.app/peptides/retatrutide) Legal status

Legal status in the United States

# Is Retatrutide legal?

Read November 18, 2026 at FDA, DEA and WADA [Published by PepVault](https://pepvault.app/guides/how-we-research)

Retatrutide has no FDA-approved product (it is in phase 3 trials), is not a federally controlled substance, and is not named on WADA’s Prohibited List (from January 1, 2027, its S0 class names peptides in general), as of November 18, 2026.

## Retatrutide at a glance

| Check | Status, read Nov 18, 2026 |
| --- | --- |
| [FDA approval](https://pepvault.app/peptides/retatrutide/legal-status#ls-fda) | Not approved; in phase 3 trials |
| [Compounding](https://pepvault.app/peptides/retatrutide/legal-status#ls-compounding) | Barred from compounding (FDA) |
| [DEA schedule](https://pepvault.app/peptides/retatrutide/legal-status#ls-dea) | Not controlled |
| [Sport (WADA)](https://pepvault.app/peptides/retatrutide/legal-status#ls-wada) | Not named; from 2027, S0 names peptides in general |

## FDA approval

Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

- [Drugs@FDA data (openFDA): applications listing “RETATRUTIDE” as an active ingredient](https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22RETATRUTIDE%22), U.S. Food and Drug Administration. Read Nov 18, 2026.
- [FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss), U.S. Food and Drug Administration. Read Nov 18, 2026.

## In clinical trials

Eli Lilly has run and is running phase 3 trials of it: ClinicalTrials.gov lists 14 phase 3 studies of retatrutide sponsored by Lilly, for obesity, type 2 diabetes, heart and kidney outcomes; 5 are completed and 9 are active or recruiting.

- [ClinicalTrials.gov record NCT07232719: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight](https://clinicaltrials.gov/study/NCT07232719), ClinicalTrials.gov (National Library of Medicine). Read Nov 18, 2026.

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Compounding

FDA writes that retatrutide cannot be used in compounding under federal law, and that it has warned telehealth companies, ingredient distributors and outsourcing facilities over it.

The source: “Retatrutide and cagrilintide cannot be used in compounding under federal law.”

- [FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss), U.S. Food and Drug Administration. Read Nov 18, 2026.

## DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

- [21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026)](https://www.ecfr.gov/current/title-21/chapter-II/part-1308), Electronic Code of Federal Regulations. Read Nov 18, 2026.
- [Controlled Substances, Alphabetical Order (dated November 17, 2026)](https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf), Drug Enforcement Administration, Diversion Control Division. Read Nov 18, 2026.

## Sport (WADA)

Until December 31, 2026: The 2026 Prohibited List doesn’t name retatrutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name retatrutide, and whether S0 reaches it still turns on its approval outside the United States.

- [World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026)](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf), World Anti-Doping Agency. Read Nov 18, 2026.
- [World Anti-Doping Code International Standard, Prohibited List 2027 (comes into effect on January 1, 2027)](https://www.wada-ama.org/sites/default/files/2026-09/2027list_en_final_clean_26_august_2026_2.pdf), World Anti-Doping Agency. Read Nov 18, 2026.
- [Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List](https://www.wada-ama.org/sites/default/files/2026-09/2027_list_explanatory_note_en_final_17_august_2026_1.pdf), World Anti-Doping Agency. Read Nov 18, 2026.

## How it is sold when it isn’t approved

FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

The source: falsely labeled “for research purposes” or “not for human consumption.”

- [FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss), U.S. Food and Drug Administration. Read Nov 18, 2026.

## What this means and doesn’t

This page reports what the agencies’ own pages said about Retatrutide in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

## About Retatrutide

### Retatrutide

- [Retatrutide in the library](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Terms

- [Research use only (RUO)](https://pepvault.app/glossary/research-use-only)
- [Compounded drug](https://pepvault.app/glossary/compounded)
- [Off-label use](https://pepvault.app/glossary/off-label)

## Questions

- ### Is Retatrutide FDA approved?

  Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug. Eli Lilly has run and is running phase 3 trials of it: ClinicalTrials.gov lists 14 phase 3 studies of retatrutide sponsored by Lilly, for obesity, type 2 diabetes, heart and kidney outcomes; 5 are completed and 9 are active or recruiting.
- ### Is Retatrutide a controlled substance?

  It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- ### Is Retatrutide banned in sport?

  Until December 31, 2026: The 2026 Prohibited List doesn’t name retatrutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name retatrutide, and whether S0 reaches it still turns on its approval outside the United States.
- ### What does FDA say about compounding Retatrutide?

  FDA writes that retatrutide cannot be used in compounding under federal law, and that it has warned telehealth companies, ingredient distributors and outsourcing facilities over it.
- ### What does FDA say about the “research use only” label?

  FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

## Read next

- [Retatrutide in the library](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)
- [Research use only (RUO)](https://pepvault.app/glossary/research-use-only)
- [Compounded drug](https://pepvault.app/glossary/compounded)
- [Off-label use](https://pepvault.app/glossary/off-label)
- [Every compound’s legal status](https://pepvault.app/peptide-legal-status)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## About Retatrutide

### Retatrutide

- [Retatrutide in the library](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Terms

- [Research use only (RUO)](https://pepvault.app/glossary/research-use-only)
- [Compounded drug](https://pepvault.app/glossary/compounded)
- [Off-label use](https://pepvault.app/glossary/off-label)

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=legal-status-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Retatrutide

- [Retatrutide in the library](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

## Legal status

- [Every compound’s legal status](https://pepvault.app/peptide-legal-status)

## The glossary

- [Research use only (RUO)](https://pepvault.app/glossary/research-use-only)
- [Compounded drug](https://pepvault.app/glossary/compounded)
- [Off-label use](https://pepvault.app/glossary/off-label)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
